Genmab A/S
Genmab’s Total Number of Voting Rights and Total Share Capital

DGAP-News: Genmab A/S

2015-05-29 / 17:05

---------------------------------------------------------------------

Company Announcement

  -- Publication of voting rights and share capital 

Copenhagen, Denmark; May 29, 2015 - Genmab A/S (OMX: GEN) announces that
pursuant to section 6 of Executive Order no. 1442 of December 13, 2013 on
Issuers' Disclosure Obligations, the total nominal value of Genmab A/S' share
capital is DKK 58,717,499 at the end of May 2015, which is made up of
58,717,499 shares of a nominal value of DKK 1 each, corresponding to 58,717,499
votes. 

About Genmab
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer.  Founded in 1999, the company currently has one
marketed antibody, Arzerra(R) (ofatumumab) for the treatment of certain chronic
lymphocytic leukemia indications and daratumumab in clinical development for
multiple myeloma and non-Hodgkin's lymphoma, in addition to other clinical
programs, and an innovative pre-clinical pipeline.  Genmab's technology base
consists of validated and proprietary next generation antibody technologies -
the DuoBody(R) platform for generation of bispecific antibodies, and the
HexaBody(R) platform which creates effector function enhanced antibodies.
Genmab's deep antibody expertise is expected to provide a stream of future
product candidates.  Partnering of selected innovative product candidates and
technologies is a key focus of Genmab's strategy and the company has alliances
with top tier pharmaceutical and biotechnology companies.  For more information
visit www.genmab.com. 

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications 
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab's most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law. 

Genmab A/S and its subsidiaries own the following trademarks: Genmab(R); the
Y-shaped Genmab logo(R); Genmab in combination with the Y-shaped Genmab logo(TM);
the DuoBody logo(R); the HexaBody logo(TM); HuMax(R); HuMax-CD20(R); DuoBody(R); HexaBody(R)
and UniBody(R). Arzerra(R) is a trademark of Novartis Pharma AG. 

Company Announcement no. 25
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark
News Source: NASDAQ OMX



---------------------------------------------------------------------

2015-05-29 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English       
Company:     Genmab A/S    
 
 
             Denmark       
ISIN:        DK0010272202  
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
363513 2015-05-29